- New York
- U.S. Patent and Trademark Office
Resa Schlossberg is head of Skadden’s intellectual property and technology transactions practice. She advises clients in numerous industries on a wide range of IP-related issues, focusing on life sciences and technology intensive representations. Her knowledge of molecular biophysics and biochemistry and research experience allow her to understand the scientific and technical aspects of matters.
Ms. Schlossberg structures, drafts, negotiates and advises on joint ventures, strategic alliances, mergers and acquisitions, and agreements such as license, research and development (R&D), collaboration, co-marketing and co-promotion, manufacturing and supply, R&D funding, synthetic royalty deals and consulting. She also conducts IP diligence and evaluates technologies for clients, including pharmaceutical, chemical, biotechnology, cosmetic, medical device and renewable energy companies, among others.
In addition to transactional work, Ms. Schlossberg has significant experience litigating patent infringement disputes in U.S. federal court, representing clients in false advertising and consumer deception matters and counseling on various strategic IP issues. She is a registered patent attorney with the U.S. Patent and Trademark Office.
Ms. Schlossberg was named one of the Top 250 Women in IP and a Transactions Star by Managing IP,
recognized among LMG Life Sciences’ top practitioners for Licensing & Collaboration and Mergers &
Acquisitions, and selected to Intellectual Asset Management’s IAM Patent 1000, where she is described as a “master at executing a deep dive into target and competitor portfolios, formulating strategies, structuring deals and successfully negotiating them.” She has also been named one of Lawdragon’s 500 Leading Lawyers in America, 500 Leading Global IP Lawyers and 500 Leading Dealmakers in America.
- Resa was lead IP counsel to TTAM Research Institute in its
$305 million acquisition of substantially all of 23andMe
Holding Co.'s assets. This transaction involved the carve-out
and transfer of a broad array of assets, including genomics
data, digital health platforms, proprietary algorithms, brand
assets and research infrastructure. Given the scope of the
technology assets and the strategic importance of genomic
and digital health IP, the transaction required careful navigation
of complex IP, data and privacy intersections to support
post-closing execution. - Resa is advising diagnostics company Exact Sciences on the
intellectual property aspects of its $23 billion acquisition by
Abbott Laboratories. Announced in November 2025, this
transaction combines Exact Sciences’ industry-leading cancer
screening and diagnostic products—including the Cologuard®
and Oncotype DX® tests, as well as advanced liquid biopsy
technologies—with Abbott’s global scale and innovation,
positioning the combined company to accelerate innovation,
expand access, and transform cancer care for millions of
patients. Unanimously approved by both boards and expected
to close in Q2 2026, the deal stands out as a landmark
“megadeal” in the life sciences sector as the largest health
care deal in 2025 and the largest deal in the diagnostics sector
ever. - Resa counseled International Flavors & Fragrances Inc. (“IFF”)
in the $2.85 billion sale of its pharma solutions business unit to
Roquette Frères S.A. (France) and the sale of its nitrocellulose
business, associated production facilities and the Walsrode
Industrial Park in Germany to Czechoslovak Group A.S. (Czech
Republic). Working closely with the IP team and broader deal
counsel, she was responsible for structuring and advising on
the allocation and transfer of intellectual property rights in both
transactions. This included: identifying and segregating the IP
assets to be transferred with each business unit, including
patents, know-how, trademarks, and related technology;
advising on transitional IP arrangements and ongoing use
rights for retained and divested businesses; and negotiating IP
provisions across the transaction documents to ensure clarity
around ownership, licensing, and operational continuity. These
carve-out transactions required close attention to the
operational integration of IP with physical sites and supply
chains, ensuring smooth separation while protecting IFF’s
retained businesses. - Resa was co-lead intellectual property counsel to Holcim Ltd.
in connection with the $30 billion spin-off and U.S. public
listing of its North American business, Amrize. This complex,
cross-border transaction separated Holcim’s U.S. and Canadian
operations into a standalone entity, requiring a comprehensive
carve-out of all business-critical assets, including intellectual
property. As co-lead IP counsel, she oversaw: managing the
identification, separation, and transfer of IP assets — including
trademarks, patents, know-how, and data — supporting
Amrize’s operations across the U.S. and Canada; advising on IP
structuring and intercompany licensing arrangements to
support both the spun-off entity and Holcim’s retained global
business; drafting and negotiating IP-related provisions in the
separation agreement, ancillary commercial agreements, and
transition services arrangements; and coordinating closely with
cross-functional and cross-border teams to align IP, branding,
and regulatory strategy for the newly listed company. Given the
scale of the spin-off and the brand and technology assets
involved, the IP workstream was essential to enabling Amrize’s
independent operations and public market readiness. - Resa is leading Skadden’s counsel to Lyell Immunopharma, Inc.
in connection with its exclusive out license from Innovative
Cellular Therapeutics, Inc. for global (ex-China) rights to ICT's
colorectal cancer program for up to $915 million. The
transaction, which was announced in November 2025, will fund
future data and progress updates from the ronde-cel clinical
program for cancer patients with large B-cell lymphoma and
data from the Phase 1 clinical trial of LYL273, a CAR T-cell
product candidate for the treatment of GCC-expressing
cancers.
- J.D. (Harlan Fiske Stone Scholar), Columbia Law School
- B.S., Molecular Biophysics and Biochemistry,
